Dimethyloxalylglycine (DMOG) and the Caspase Inhibitor “Ac-LETD-CHO” Protect Neuronal ND7/23 Cells of Gluocotoxicity

Abstract

It well known that long-lasting hyperglycaemia disrupts neuronal function and leads to neuropathy and other neurodegenerative diseases. The α-ketoglutarate analogue (DMOG) and the caspase-inhibitor “Ac-LETD-CHO are potential neuroprotective molecules. Whether their protections may also extend glucotoxicity-induced neuropathy is not known. Herein, we evaluated the possible cell-protective effects of DMOG and Ac-LETD-CHO against hyperglycaemia-induced reactive oxygen species and apoptosis in ND7/23 neuronal cells. The impact of glucotoxicity on the expression of HIF-1α and a panel of micro-RNAs of significance in hyperglycaemia and apoptosis was also investigated.

ND7/23 cells cultured under hyperglycaemic conditions showed decreased cell viability and elevated levels of ROS production in a dose- and time-dependent manner. However, presence DMOG (500 µM) and/or Ac-LETD-CHO (50 µM) counteracted this effect and increase cell viability concomitant with reduction in ROS production, DNA damage and apoptosis. AcLETD-CHO suppressed hyperglycaemia-induced caspase 3 activation in ND7/23 cells. Both DMOG and Ac-LETD-CHO increased HIF-1α expression paralleled with the suppression of miR-126–5p, miR-128–3p and miR-181 expression and upregulation of miR-26b, 106a-5p, 106b-5p, 135a-5p, 135b-5p, 138–5p, 199a-5p, 200a-3p and 200c-3p expression.

We demonstrate a mechanistic link for the DMOG and Ac-LETD-CHO protection against hyperglycaemia-induced neuronal dysfunction, DNA damage and apoptosis and thereby propose that pharmacological agents mimicking these effects may represent a promising novel therapy for the hyperglycaemia-induced neuropathy.

Key words

diabetic neuropathy - hyperglycaemia - apoptosis - HIF-1α - DMOG - Ac-LETD-CHO

Publication History

Received: 30 January 2019
Received: 28 March 2019

Accepted: 14 May 2019

Article published online:
11 June 2019

• References

• 1 McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. The Lancet 2012; 379: 2291-2299
• 2 Das F, Dey N, Venkatesan B. et al. High glucose upregulation of early-onset Parkinson’s disease protein DJ-1 integrates the PRAS40/TORC1 axis to mesangial cell hypertrophy. Cellular Signalling 2011; 23: 1311-1319
• 3 Newrick P, Wilson A, Jakubowski J. et al. Sural nerve oxygen tension in diabetes. Br Med J (Clin Res Ed) 1986; 293: 1053-1054
• 4 Matsuzaki T, Sasaki K, Tanizaki Y. et al. Insulin resistance is associated with the pathology of Alzheimer disease The Hisayama Study. Neurology 2010; 75: 764-770
• 5 Kumar P, Rao GN, Pal BB. et al. Hyperglycemia-induced oxidative stress induces apoptosis by inhibiting PI3-kinase/Akt and ERK1/2 MAPK mediated signaling pathway causing downregulation of 8-oxoG-DNA glycosylase levels in glial cells. The International Journal of Biochemistry & Cell Biology 2014; 53: 302-319
• 6 Seaquist ER. The final frontier: how does diabetes affect the brain?. Diabetes 2010; 59: 4-5
• 7 Isoe T, Makino Y, Mizumoto K. et al. High glucose activates HIF-1-mediated signal transduction in glomerular mesangial cells through a carbohydrate response element binding protein. Kidney International 2010; 78: 48-59
• 8 Abdul-Ghani MA, DeFronzo RA. Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus. Current Diabetes Reports 2008; 8: 173
• 9 Vincent AM, Mclean LL, Backus C. et al. Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. The FASEB Journal 2005; 19: 638-640
• 10 Greijer A, Van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. Journal of Clinical Pathology 2004; 57: 1009-1014
• 11 Vincent AM, Kato K, McLean LL. et al. Sensory neurons and schwann cells respond to oxidative stress by increasing antioxidant defense mechanisms. Antioxidants & Redox Signaling 2009; 11: 425-438
• 12 Vanessa Fiorentino T, Prioletta A, Zuo P. et al. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Current Pharmaceutical Design 2013; 19: 5695-5703
• 13 Xie C, Xu M, Lu D. et al. Candidate genes and microRNAs for glioma pathogenesis and prognosis based on gene expression profiles. Molecular Medicine Reports 2018; 18: 2715-2723
• 14 Liu XS, Fan B, Szalad A. et al. MicroRNA-146a mimics reduce the peripheral neuropathy in type ii diabetic mice. Diabetes 2017; db161182
• 15 Esteves JV, Yonamine CY, Pinto-Junior DC. et al. Diabetes modulates MicroRNAs 29b-3p, 29c-3p, 199a-5p and 532-3p expression in muscle: Possible role in GLUT4 and HK2 repression. Frontiers in Endocrinology 2018; 9:
• 16 Wang F, Ma H, Liang W-J. et al. Lovastatin upregulates microRNA-29b to reduce oxidative stress in rats with multiple cardiovascular risk factors. Oncotarget 2017; 8: 9021
• 17 Zhou S, Zhang S, Wang Y. et al. MiR-21 and miR-222 inhibit apoptosis of adult dorsal root ganglion neurons by repressing TIMP3 following sciatic nerve injury. Neuroscience Letters 2015; 586: 43-49
• 18 Vordermark D, Kraft P, Katzer A. et al. Glucose requirement for hypoxic accumulation of hypoxia-inducible factor-1α (HIF-1α). Cancer Letters 2005; 230: 122-133
• 19 Koivunen P, Serpi R, Dimova EY. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition in cardiometabolic diseases. Pharmacological Research 2016; 114: 265-273
• 20 Neitemeier S, Dolga A, Honrath B. et al. Inhibition of HIF-prolyl-4-hydroxylases prevents mitochondrial impairment and cell death in a model of neuronal oxytosis. Cell Death & Disease 2017; 7: e2214
• 21 Selvaraju V, Parinandi NL, Adluri RS. et al. Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF–prolyl 4-hydroxylases for treatment of ischemic diseases. Antioxidants & Redox Signaling 2014; 20: 2631-2665
• 22 Zhdanov AV, Okkelman IA, Collins FW. et al. A novel effect of DMOG on cell metabolism: direct inhibition of mitochondrial function precedes HIF target gene expression. Biochimica et Biophysica Acta (BBA)-Bioenergetics 2015 1847; 1254-1266
• 23 Sen T, Sen N. Treatment with an activator of hypoxia-inducible factor 1, DMOG provides neuroprotection after traumatic brain injury. Neuropharmacology 2016; 107: 79-88
• 24 Lomb DJ, Straub JA, Freeman RS. Prolyl hydroxylase inhibitors delay neuronal cell death caused by trophic factor deprivation. Journal of Neurochemistry 2007; 103: 1897-1906
• 25 Hams E, Saunders SP, Cummins EP. et al. The hydroxylase inhibitor DMOG attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B-1 cells. Shock (Augusta, Ga) 2011; 36: 295
• 26 Ahn J-m, You SJ, Y-M Lee. et al. Hypoxia-inducible factor activation protects the kidney from gentamicin-induced acute injury. PloS one 2012; 7: e48952
• 27 Duscher D, Januszyk M, Maan ZN. et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plastic and Reconstructive Surgery 2017; 139: 695e-706e
• 28 Yun CY, Liu S, Lim SF. et al. Specific inhibition of caspase-8 and-9 in CHO cells enhances cell viability in batch and fed-batch cultures. Metabolic Engineering 2007; 9: 406-418
• 29 Boulton AJ, Vinik AI, Arezzo JC. et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962
• 30 Sima A. New insights into the metabolic and molecular basis for diabetic neuropathy. Cellular and Molecular Life Sciences CMLS 2003; 60: 2445-2464
• 31 Schmeichel AM, Schmelzer JD, Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003; 52: 165-171
• 32 Catrina S-B, Okamoto K, Pereira T. et al. Hyperglycemia regulates hypoxia-inducible factor-1α protein stability and function. Diabetes 2004; 53: 3226-3232
• 33 Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharmaceutica Sinica B 2015; 5: 378-389
• 34 Wang GL, Jiang B-H, Rue EA. et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences 1995; 92: 5510-5514
• 35 Li T, Lu C, Xia Z. et al. Inhibition of caspase-8 attenuates neuronal death induced by limbic seizures in a cytochrome c-dependent and Smac/DIABLO-independent way. Brain Research 2006; 1098: 204-211
• 36 Valente MJ, Araújo AM, Bastos MdL. et al. Editor’s Highlight: Characterization of hepatotoxicity mechanisms triggered by designer cathinone drugs (β-Keto Amphetamines). Toxicological Sciences 2016; 153: 89-102
• 37 Ricci J-E, Gottlieb RA, Green DR. Caspase-mediated loss of mitochondrial function and generation of reactive oxygen species during apoptosis. The Journal of Cell Biology 2003; 160: 65-75
• 38 Zhu Y, Li M, Wang X. et al. Caspase cleavage of cytochrome c1 disrupts mitochondrial function and enhances cytochrome c release. Cell Research 2012; 22: 127
• 39 Botusan IR, Sunkari VG, Savu O. et al. Stabilization of HIF-1α is critical to improve wound healing in diabetic mice. Proceedings of the National Academy of Sciences 2008; 105: 19426-19431
• 40 Tenneti L, D'emilia DM, Troy CM. et al. Role of caspases in N-methyl-D-aspartate-induced apoptosis in cerebrocortical neurons. Journal of Neurochemistry 1998; 71: 946-959
• 41 Simon H-U, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000; 5: 415-418
• 42 Thangarajah H, Vial IN, Grogan RH. et al. HIF-1α dysfunction in diabetes. Cell Cycle 2010; 9: 75-79